<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086020</url>
  </required_header>
  <id_info>
    <org_study_id>RJH20100101</org_study_id>
    <nct_id>NCT01086020</nct_id>
  </id_info>
  <brief_title>Atorvastatin Plus Ezetimibe on Coronary Plaque Progression</brief_title>
  <acronym>AEPP</acronym>
  <official_title>Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      Atherosclerosis is a progressive disease. Lipid lowering therapy was the standard treatment
      for patients with coronary artery disease. Studies indicated that coronary artery plaque
      progression had positive relationship with the plasma cholesterol level, and could be halted
      or reversed by intensive statin therapy (such as 20-40 mg/d atorvastatin). Ezetimibe plus
      statin could further lowered blood cholesterol level. Here the investigators hypothesize that
      same cholesterol lowering level by routing dose of atorvastatin or lower dose of atorvastatin
      plus ezetimibe could achieve the same effect on coronary artery plaque cessation or
      regression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of coronary artery plaque volume</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint was the change of coronary artery plaque volume measured by intravascular ultrasound (IVUS) at one year after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>composite of adverse cardiac events</measure>
    <time_frame>2 years</time_frame>
    <description>The secondary endpoint was the composite of adverse cardiac events (MACE), including cardiac death, non-fatal infarction and target vessel revascularization at two years after randomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>atorvastatin and ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years</description>
    <arm_group_label>atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin plus ezetimibe</intervention_name>
    <description>Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years</description>
    <arm_group_label>atorvastatin and ezetimibe</arm_group_label>
    <other_name>Lipitor and ezetrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to receive the coronary angiography and potential PCI therapy

        Exclusion Criteria:

          -  Patients was treated by statins before randomization

          -  Patient with ≤ 20% and ≥ 70% coronary narrowing and target lesion

          -  ST elevation myocardial infarction less than 7 days

          -  Without informed consent

          -  Abnormal liver function before randomization, (AST, ALT ≥ULN)

          -  Active hepatitis or muscular disease

          -  Impaired renal function with serum creatinine level &gt; 3mg/dl

          -  Impaired left ventricular function with LVEF &gt; 30%

          -  Participate in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weifeng Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruiyan Zhang, MD</last_name>
    <phone>862164370045</phone>
    <phone_ext>665215</phone_ext>
    <email>zhangruiyan@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xin Chen, MD</last_name>
    <phone>862164370045</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital,</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiyan Zhang, MD</last_name>
      <phone>862164370045</phone>
      <phone_ext>665215</phone_ext>
      <email>zhangruiyan@263.net</email>
    </contact>
    <contact_backup>
      <last_name>Xin Chen, MD</last_name>
      <phone>862164370045</phone>
      <phone_ext>665380</phone_ext>
      <email>rjchenxin@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ruiyan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2010</study_first_posted>
  <last_update_submitted>April 1, 2011</last_update_submitted>
  <last_update_submitted_qc>April 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Weifeng Shen</name_title>
    <organization>ruijin hospital, shanghai jiao tong university school of medicine</organization>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>coronary plaque</keyword>
  <keyword>regression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

